Delving into the Latest Updates on Sarsasapogenin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(25R)-5beta-Spirostan-3beta-ol, (25R)-Spirostan-3beta-ol, Isosarsapogenin

+ [7]

Target

BDNF x GDNFR

Mechanism

BDNF agonists(Brain-derived neurotrophic factor agonists), GDNFR agonists(Glial cell line-derived neurotrophic factor receptors agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication-

Inactive Indication

Alzheimer DiseaseYoung onset Parkinson disease

Originator Organization

Ixico Plc

Active Organization-

Inactive Organization

Phytopharm Plc

Drug Highest PhasePendingPhase 2

First Approval Date-

RegulationOrphan Drug (EU)

Login to view timeline

Structure

Molecular FormulaC27H44O3

InChIKeyGMBQZIIUCVWOCD-UQHLGXRBSA-N

CAS Registry126-18-1

A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS). It is hypothesised that PYM50028 will be safe and well tolerated in this study and demonstrate therapeutic benefit in this patient population.

Start Date01 Nov 2010

Sponsor / Collaborator

Phytopharm Plc

NCT00875316 / CompletedPhase 1

A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month

Phytopharm plc is developing Cogane™ which is a new medicine for the treatment of Parkinson's disease (PD). The purpose of the study is to find out if Cogane is safe and well tolerated in both healthy volunteers and Parkinson's disease patients and to determine if there is a difference in the way that the body deals with Cogane (pharmacokinetics) between these two groups.
It is expected that the study will prove that Cogane™ is safe and well tolerated and will provide us with a pharmacokinetic profile for both subject groups.

Start Date01 Apr 2009

Sponsor / Collaborator

Phytopharm Plc

NCT00130429 / CompletedPhase 2

Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type

The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.

Start Date01 Jan 2004

Sponsor / Collaborator

Phytopharm Plc

100 Clinical Results associated with Sarsasapogenin

Login to view more data

100 Translational Medicine associated with Sarsasapogenin

Login to view more data

100 Patents (Medical) associated with Sarsasapogenin

Login to view more data

163

Literatures (Medical) associated with Sarsasapogenin

01 Feb 2025·Food Chemistry

Determination of the biological activities of endemic Allium lazikkiyense and its phytochemical profile by LC-MS/MS analysis

Article

Author: Yilmaz-Ozden, Tugba ; Celikok, Yasin ; Duranay, Servet ; Hasbal-Celikok, Gozde ; Azami, Faiza Tabassum ; Kocyigit, Mine

This study investigated the phytochemical contents and in vitro antioxidant, enzyme inhibitory and anticancer properties of ethanol, methanol, and dichloromethane extracts prepared from aerial parts and onion peels of endemic Allium lazikkiyense Koçyiğit, Özhatay & E.Kaya. Ethanol extracts showed the highest antioxidant activity among the all extracts in terms of total phenolic and flavonoid contents as well as DPPH scavenging and iron reducing potentials. LC-MS/MS analysis results showed that aerial parts rich in fumaric acid, p-coumaric acid, ascorbic acid and hyperoside while onion peels rich in sarsasapogenin, caffeic acid and fumaric acid. Dichloromethane extracts showed a strong inhibitory effect on α-glucosidase, while all extracts exhibited low inhibitory activity on α-amylase, acetylcholinesterase and butyrylcholinesterase. Also, extracts from onion peels exhibited potent cytotoxic effect against MCF7 human breast cancer cells. The present study revealed that A. lazikkiyense could be a good natural source for antioxidant, α-glucosidase inhibitory, and anticancer activities.

01 Feb 2024·Heliyon

Sarsasapogenin regulates the immune microenvironment through MAPK/NF-kB signaling pathway and promotes functional recovery after spinal cord injury

Article

Author: Chang, Nianwei ; Wang, Liyue ; Liu, Song ; Fang, Bing ; Zhou, Mi ; Ning, Guangzhi ; Ma, Hongpeng

Spinal cord injury (SCI) occurs as a result of traumatic events that damage the spinal cord, leading to motor, sensory, or autonomic function impairment. Sarsasapogenin (SA), a natural steroidal compound, has been reported to have various pharmacological applications, including the treatment of inflammation, diabetic nephropathy, and neuroprotection. However, the therapeutic efficacy and underlying mechanisms of SA in the context of SCI are still unclear. This research aimed to investigate the therapeutic effects and mechanisms of SA against SCI by integrating network pharmacology analysis and experimental verification. Network pharmacology results suggested that SA may effectively treat SCI by targeting key targets such as TNF, RELA, JUN, MAPK14, and MAPK8. The underlying mechanism of this treatment may involve the MAPK (JNK) signaling pathway and inflammation-related signaling pathways such as TNF and Toll-like receptor signaling pathways. These findings highlight the therapeutic potential of SA in SCI treatment and provide valuable insights into its molecular mechanisms of action. In vivo experiments confirmed the reparative effect of SA on SCI in rats and suggested that SA could repair SCI by modulating the immune microenvironment. In vitro experiments further investigated how SA regulates the immune microenvironment by inhibiting the MAPK/NF-kB pathways. Overall, this study successfully utilized a combination of network pharmacology and experimental verification to establish that SA can regulate the immune microenvironment via the MAPK/NF-kB signaling pathway, ultimately facilitating functional recovery from SCI. Furthermore, these findings emphasize the potential of natural compounds from traditional Chinese medicine as a viable therapy for SCI treatment.

01 Jan 2024·Journal of Ethnopharmacology

Study on the neuroprotective effect of Zhimu-Huangbo extract on mitochondrial dysfunction in HT22 cells induced by D-galactose by promoting mitochondrial autophagy

Article

Author: Xue, Ao ; Zhang, Ning ; Yang, Meng ; Wu, Jianli ; Lei, Xia ; Zhao, Hongmei ; Li, Xue ; Zhao, Deping ; Zhao, Chenyu ; Zhao, Can

ETHNOPHARMACOLOGICAL RELEVANCEZhimu-Huangbo (ZB) herb pair is a common prescription drug used by physicians of all dynasties, and has significant neuroprotective effect, such as the ZB can significantly promote neuronal cell regeneration, repair neuronal damage, and improve cognitive disorders. However, its ingredients are urgently needed to be identified and mechanisms is remained unclear.AIM OF THE STUDYUsing ultra performance liquid chromatography-quadrupole-time of flight-mass spectrometry (UPLC-Q-TOF-MS), the study of neuroprotective mechanism of Zhimu-Huangbo extract (ZBE) is investigated, and the network pharmacology technology and experimental validation is also performed.MATERIAL AND METHODSFirstly, UPLC-Q-TOF-MS technology was used to characterize the chemical components contained in the ZBE. After that, the TCMSP database and the Swiss Target Prediction method were used to search for potential target genes for ZBE compounds. At the same time, the OMIM and GeneCards disease databases were used to search for Alzheimer's disease (AD) targets and expanded with the GEO database. Then, GO and KEGG enrichment analysis was performed using OECloud tools. Subsequently, the potential mechanism of ZBE therapeutic AD predicted by network pharmacological analysis was experimentally studied and verified in vitro.RESULTSIn the UPLC-Q-TOF-MS analysis of the ZBE, a total of 39 compounds were characterized including Neomangiferin, Oxyberberine, Timosaponin D, Berberine, Timosaponin A-III, Anemarsaponin E, Timosaponin A-I, Smilagenin and so on. A total of 831 potential targets and 13995 AD-related target genes were screened. A further analysis revealed the number of common targets between ZBE and AD is 698. Through GO and KEGG enrichment analysis, we found that ZBE's anti-AD targets were significantly enriched in autophagy and mitochondrial autophagy related pathways. The results of cell experiments also confirmed that ZBE can promote mitochondrial autophagy induced by D-galactose (D-gal) HT22 cells through the PTEN-induced kinase 1/Parkin (PINK1/Parkin) pathway.CONCLUSIONZBE can promote autophagy of mitochondria and play a protective role on damaged neurons.

100 Deals associated with Sarsasapogenin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sarsasapogenin	-	DB05450

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Young onset Parkinson disease	Phase 2	RO	Phytopharm Plc	01 Nov 2010
Young onset Parkinson disease	Phase 2	HU	Phytopharm Plc	01 Nov 2010
Young onset Parkinson disease	Phase 2	PL	Phytopharm Plc	01 Nov 2010
Young onset Parkinson disease	Phase 2	CZ	Phytopharm Plc	01 Nov 2010
Young onset Parkinson disease	Phase 2	US	Phytopharm Plc	01 Nov 2010
Young onset Parkinson disease	Phase 2	GB	Phytopharm Plc	01 Nov 2010
Young onset Parkinson disease	Phase 2	DE	Phytopharm Plc	01 Nov 2010
Young onset Parkinson disease	Phase 2	RS	Phytopharm Plc	01 Nov 2010
Young onset Parkinson disease	Phase 2	CA	Phytopharm Plc	01 Nov 2010
Alzheimer Disease	Phase 2	GB	Phytopharm Plc	01 Jan 2004